Evelien Dekker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Evelien Dekker has a total of 134 co-authors. Here are the top co-authors by number of shared publications:
P. Fockens
Department of Gastroenterology and Hepatology, Academic Medical Centre, Amsterdam, The Netherlands
4 shared publications- Paul Fockens
Gastroenterology and Hepatology, Academic Medical Center, Amsterdam, Netherlands
4 shared publications - Patrick Mm Bossuyt
Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Academic Medical Centre, University of Amsterdam, Amsterdam, The Netherlands.
3 shared publications - Eelco J. R. de Graaf
IJsselland Hospital
2 shared publications - Ernst J. Kuipers
Department of Gastroenterology and Hepatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands
2 shared publications - Monique E. van Leerdam
Department of Gastroenterology and Hepatology, Leiden University Medical Center, Leiden, The Netherlands
2 shared publications
Latest Publications
- Open Access
- 25 April 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 465
Impact of differences in adenoma and proximal serrated polyp detection rate on the long-term effectiveness of FIT-based colorectal cancer screening
Both the adenoma detection rate (ADR) and proximal serrated polyp detection rate (PSPDR) vary among endoscopists. It is unclear how these variations influence colorectal cancer (CRC) screening effectiveness. We evaluated the effect of variation in these detection rates on the long-term impact of fecal immunochemical test (FIT) based screening. The Adenoma and Serrated pathway to Colorectal CAncer (ASCCA) model was set up to simulate the Dutch national biennial FIT-based CRC screening program between 2014 and 2044. Adherence to FIT and colonoscopy was 73 and 92%. Besides a ‘no screening scenario’, several screening scenarios varying in ADR and PSPDR were evaluated. Using the available literature on colonoscopy miss rates led to a base-case ADR of 59% and PSPDR of 11%, which were varied with intervals of 3 and 2%. Compared to no screening, FIT-screening in the base-case scenario reduced long-term mortality with 51.8%. At a fixed PSPDR of 11%, an increase in ADR from 44 to 62% would result in a 10.7% difference in mortality reduction. Using a fixed ADR of 59%, changing the PSPDR from 3 to 15% did not substantially influence long-term mortality (51.0 to 52.3%). An increase in ADR gradually reduces CRC burden in a FIT-based screening program, whereas an increase in PSPDR only minimally influences long-term outcomes at a population-level. The limited effect of the PSPDR can be explained by the limited sensitivity of FIT for serrated polyps (SPs). Other triage modalities aiming to detect relevant SPs should be explored.
- 25 April 2018
- Published by Springer Nature in BMC Cancer
- Vol. 18 (1) , 465
Open AccessImpact of differences in adenoma and proximal serrated polyp detection rate on the long-term effectiveness of FIT-based colorectal cancer screening
Both the adenoma detection rate (ADR) and proximal serrated polyp detection rate (PSPDR) vary among endoscopists. It is unclear how these variations influence colorectal cancer (CRC) screening effectiveness. We evaluated the effect of variation in these detection rates on the long-term impact of fecal immunochemical test (FIT) based screening. The Adenoma and Serrated pathway to Colorectal CAncer (ASCCA) model was set up to simulate the Dutch national biennial FIT-based CRC screening program between 2014 and 2044. Adherence to FIT and colonoscopy was 73 and 92%. Besides a ‘no screening scenario’, several screening scenarios varying in ADR and PSPDR were evaluated. Using the available literature on colonoscopy miss rates led to a base-case ADR of 59% and PSPDR of 11%, which were varied with intervals of 3 and 2%. Compared to no screening, FIT-screening in the base-case scenario reduced long-term mortality with 51.8%. At a fixed PSPDR of 11%, an increase in ADR from 44 to 62% would result in a 10.7% difference in mortality reduction. Using a fixed ADR of 59%, changing the PSPDR from 3 to 15% did not substantially influence long-term mortality (51.0 to 52.3%). An increase in ADR gradually reduces CRC burden in a FIT-based screening program, whereas an increase in PSPDR only minimally influences long-term outcomes at a population-level. The limited effect of the PSPDR can be explained by the limited sensitivity of FIT for serrated polyps (SPs). Other triage modalities aiming to detect relevant SPs should be explored.
- 27 March 2018
- Published by Georg Thieme Verlag KG
- Vol. 50 (04) , OP271
RISK FACTORS FOR FALSE-POSITIVE AND FALSE-NEGATIVE FECAL IMMUNOCHEMICAL TEST RESULTS IN COLORECTAL CANCER SCREENING: SYSTEMATIC REVIEW AND META-ANALYSIS
Aims: Colorectal cancer (CRC) screening using fecal immunochemical tests (FIT) may reduce CRC-related mortality but its effectiveness is affected by FIT's limited accuracy. Identifying individuals at increased risk of a false FIT result could improve screening, but available evidence is conflicting. We performed a systematic review with meta-analysis on risk factors for false-positive and false-negative FIT results in CRC-screening. Methods: A systematic search in MEDLINE, EMBASE, Cochrane Library identified publications on risk factors, known at the time of screening invitation, associated with false FIT results in a CRC-screening setting. Summary relative risk ratios and 95% confidence intervals were calculated for each risk-factor through meta-analysis. Results: Seventeen studies were included for analysis, with data on 54499 participants. In meta-analysis (table 1), male sex (RR 0.86, CI 0.82 – 0.90), higher age (RR 0.92, CI 0.86 – 0.99) and elevated fasting blood glucose (RR 0.90, CI 0.83 – 0.98) were each associated with a significantly lower risk of a false-positive result, whereas participants with hemorrhoids had a higher risk (RR 1.27, CI 1.17 – 1.37). The use of anti-coagulants was most frequently studied: without a significant effect on FIT-positivity. Males (RR 1.84, CI 1.54 – 2.21), participants with a CRC family history (RR 1.56, CI 1.20 – 2.04), elevated fasting blood glucose (RR 1.29, CI 1.01 – 1.64), hypertension (RR 1.48, CI 1.21 – 1.82) or obesity (RR 1.38, CI 1.17 – 1.62) were at higher risk of false-negative results, while participants with hemorrhoids had a lower risk (RR 0.61, CI 0.45 – 0.83). Conclusions: Multiple risk factors, known at time of invitation, are associated with false FIT results in CRC-screening. This information can be used to identify populations at high risk to receive false reassurance after a negative result, or unnecessary colonoscopies after a positive result, and hence further optimize of CRC-screening effectiveness.
- 27 March 2018
- Published by Georg Thieme Verlag KG
- Vol. 50 (04) , OP271
RISK FACTORS FOR FALSE-POSITIVE AND FALSE-NEGATIVE FECAL IMMUNOCHEMICAL TEST RESULTS IN COLORECTAL CANCER SCREENING: SYSTEMATIC REVIEW AND META-ANALYSIS
Aims: Colorectal cancer (CRC) screening using fecal immunochemical tests (FIT) may reduce CRC-related mortality but its effectiveness is affected by FIT's limited accuracy. Identifying individuals at increased risk of a false FIT result could improve screening, but available evidence is conflicting. We performed a systematic review with meta-analysis on risk factors for false-positive and false-negative FIT results in CRC-screening. Methods: A systematic search in MEDLINE, EMBASE, Cochrane Library identified publications on risk factors, known at the time of screening invitation, associated with false FIT results in a CRC-screening setting. Summary relative risk ratios and 95% confidence intervals were calculated for each risk-factor through meta-analysis. Results: Seventeen studies were included for analysis, with data on 54499 participants. In meta-analysis (table 1), male sex (RR 0.86, CI 0.82 – 0.90), higher age (RR 0.92, CI 0.86 – 0.99) and elevated fasting blood glucose (RR 0.90, CI 0.83 – 0.98) were each associated with a significantly lower risk of a false-positive result, whereas participants with hemorrhoids had a higher risk (RR 1.27, CI 1.17 – 1.37). The use of anti-coagulants was most frequently studied: without a significant effect on FIT-positivity. Males (RR 1.84, CI 1.54 – 2.21), participants with a CRC family history (RR 1.56, CI 1.20 – 2.04), elevated fasting blood glucose (RR 1.29, CI 1.01 – 1.64), hypertension (RR 1.48, CI 1.21 – 1.82) or obesity (RR 1.38, CI 1.17 – 1.62) were at higher risk of false-negative results, while participants with hemorrhoids had a lower risk (RR 0.61, CI 0.45 – 0.83). Conclusions: Multiple risk factors, known at time of invitation, are associated with false FIT results in CRC-screening. This information can be used to identify populations at high risk to receive false reassurance after a negative result, or unnecessary colonoscopies after a positive result, and hence further optimize of CRC-screening effectiveness.
- Open Access
- 21 July 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-8
A multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer
Rectal cancer surgery is accompanied with high morbidity and poor long term functional outcome. Screening programs have shown a shift towards more early staged cancers. Patients with early rectal cancer can potentially benefit significantly from rectal preserving therapy. For the earliest stage cancers, local excision is sufficient when the risk of lymph node disease and subsequent recurrence is below 5 %. However, the majority of early cancers are associated with an intermediate risk of lymph node involvement (5–20 %) suggesting that local excision alone is not sufficient, while completion radical surgery, which is currently standard of care, could be a substantial overtreatment for this group of patients. In this multicentre randomised trial, patients with an intermediate risk T1-2 rectal cancer, that has been locally excised using an endoluminal technique, will be randomized between adjuvant chemo-radiotherapylimited to the mesorectum and standard completion total mesorectal excision (TME). To strictly monitor the risk of locoregional recurrence in the experimental arm and enable early salvage surgery, there will be additional follow up with frequent MRI and endoscopy. The primary outcome of the study is three-year local recurrence rate. Secondary outcomes are morbidity, disease free and overall survival, stoma rate, functional outcomes, health related quality of life and costs. The design is a non inferiority study with a total sample size of 302 patients. The results of the TESAR trial will potentially demonstrate that adjuvant chemoradiotherapy is an oncological safe treatment option in patients who are confronted with the difficult clinical dilemma of a radically removed intermediate risk early rectal cancer by polypectomy or transanal surgery that is conventionally treated with subsequent radical surgery. Preserving the rectum using adjuvant radiotherapy is expected to significantly improve morbidity, function and quality of life if compared to completion TME surgery. NCT02371304 , registration date: February 2015
- 21 July 2016
- Published by Springer Nature in BMC Cancer
- Vol. 16 (1) , 1-8
Open AccessA multi-centred randomised trial of radical surgery versus adjuvant chemoradiotherapy after local excision for early rectal cancer
Rectal cancer surgery is accompanied with high morbidity and poor long term functional outcome. Screening programs have shown a shift towards more early staged cancers. Patients with early rectal cancer can potentially benefit significantly from rectal preserving therapy. For the earliest stage cancers, local excision is sufficient when the risk of lymph node disease and subsequent recurrence is below 5 %. However, the majority of early cancers are associated with an intermediate risk of lymph node involvement (5–20 %) suggesting that local excision alone is not sufficient, while completion radical surgery, which is currently standard of care, could be a substantial overtreatment for this group of patients. In this multicentre randomised trial, patients with an intermediate risk T1-2 rectal cancer, that has been locally excised using an endoluminal technique, will be randomized between adjuvant chemo-radiotherapylimited to the mesorectum and standard completion total mesorectal excision (TME). To strictly monitor the risk of locoregional recurrence in the experimental arm and enable early salvage surgery, there will be additional follow up with frequent MRI and endoscopy. The primary outcome of the study is three-year local recurrence rate. Secondary outcomes are morbidity, disease free and overall survival, stoma rate, functional outcomes, health related quality of life and costs. The design is a non inferiority study with a total sample size of 302 patients. The results of the TESAR trial will potentially demonstrate that adjuvant chemoradiotherapy is an oncological safe treatment option in patients who are confronted with the difficult clinical dilemma of a radically removed intermediate risk early rectal cancer by polypectomy or transanal surgery that is conventionally treated with subsequent radical surgery. Preserving the rectum using adjuvant radiotherapy is expected to significantly improve morbidity, function and quality of life if compared to completion TME surgery. NCT02371304 , registration date: February 2015
- 1 June 2015
- Published by Elsevier in Cancer Epidemiology
- Vol. 39 (3) , 388-393
Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening
- 1 June 2015
- Published by Elsevier in Cancer Epidemiology
- Vol. 39 (3) , 388-393
Participation, yield, and interval carcinomas in three rounds of biennial FIT-based colorectal cancer screening
- 1 November 2014
- Published by Elsevier in Value in Health
- Vol. 17 (7) , A323
Long-Term Impact of the Dutch Colorectal Cancer Screening Programme on Cancer Incidence: Exploration of the Serrated Pathway
- 1 November 2014
- Published by Elsevier in Value in Health
- Vol. 17 (7) , A323
Long-Term Impact of the Dutch Colorectal Cancer Screening Programme on Cancer Incidence: Exploration of the Serrated Pathway
- 1 July 2014
- Published by Elsevier in Gastroenterology
- Vol. 147 (1) , 88-95
Incidence of Colonic Neoplasia in Patients With Serrated Polyposis Syndrome Who Undergo Annual Endoscopic Surveillance
- 1 July 2014
- Published by Elsevier in Gastroenterology
- Vol. 147 (1) , 88-95
Incidence of Colonic Neoplasia in Patients With Serrated Polyposis Syndrome Who Undergo Annual Endoscopic Surveillance
- 19 November 2013
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 46 (03) , 219-224
Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy
Background and study aims: Serrated polyps of the large intestine comprise a heterogeneous group of lesions with distinct histological and malignant features. The aim of the study was to estimate the prevalence of serrated polyp subtypes in a cohort of individuals undergoing screening colonoscopy, and to identify associations between the detection of serrated polyp subtypes and advanced neoplasia. Patients and methods: Data on serrated polyps, adenomas, and cancers were collected from participants of a randomized screening trial that compared colonoscopy with computed tomography colonography. Only data from participants in the colonoscopy arm were used. Logistic regression analyses were performed to identify associations between patients’ age, sex, and prevalence of the different types of serrated polyps and to identify associations between the detection of these polyps and advanced neoplasia (defined as an adenoma ≥ 10 mm, villous component, high grade dysplasia or colorectal cancer). Results: A total of 1426 screen-naïve individuals (51 % male) with a median age of 60 years (IQR 55 – 65) were included. The prevalence of hyperplastic polyps, sessile serrated adenomas/polyps (SSA/Ps), and traditional serrated adenomas (TSAs) was 23.8 %, 4.8 %, and 0.1 %, respectively. SSA/Ps comprised 7.3 % of all polyps. No differences based on age or sex were observed in the prevalence of SSA/Ps. Proximal and large (≥ 10 mm) hyperplastic polyps, as well as proximal and large (≥ 10 mm) SSA/Ps, were associated with synchronous advanced neoplasia. Conclusions: Serrated polyps, including SSA/Ps, were frequently encountered in routine screening colonoscopies. Large and proximal hyperplastic polyps, as well large and proximal SSA/Ps, were associated with advanced neoplasia.
- 19 November 2013
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 46 (03) , 219-224
Prevalence of serrated polyps and association with synchronous advanced neoplasia in screening colonoscopy
Background and study aims: Serrated polyps of the large intestine comprise a heterogeneous group of lesions with distinct histological and malignant features. The aim of the study was to estimate the prevalence of serrated polyp subtypes in a cohort of individuals undergoing screening colonoscopy, and to identify associations between the detection of serrated polyp subtypes and advanced neoplasia. Patients and methods: Data on serrated polyps, adenomas, and cancers were collected from participants of a randomized screening trial that compared colonoscopy with computed tomography colonography. Only data from participants in the colonoscopy arm were used. Logistic regression analyses were performed to identify associations between patients’ age, sex, and prevalence of the different types of serrated polyps and to identify associations between the detection of these polyps and advanced neoplasia (defined as an adenoma ≥ 10 mm, villous component, high grade dysplasia or colorectal cancer). Results: A total of 1426 screen-naïve individuals (51 % male) with a median age of 60 years (IQR 55 – 65) were included. The prevalence of hyperplastic polyps, sessile serrated adenomas/polyps (SSA/Ps), and traditional serrated adenomas (TSAs) was 23.8 %, 4.8 %, and 0.1 %, respectively. SSA/Ps comprised 7.3 % of all polyps. No differences based on age or sex were observed in the prevalence of SSA/Ps. Proximal and large (≥ 10 mm) hyperplastic polyps, as well as proximal and large (≥ 10 mm) SSA/Ps, were associated with synchronous advanced neoplasia. Conclusions: Serrated polyps, including SSA/Ps, were frequently encountered in routine screening colonoscopies. Large and proximal hyperplastic polyps, as well large and proximal SSA/Ps, were associated with advanced neoplasia.
- Open Access
- 19 June 2012
- Published by Springer Nature in BMC Gastroenterology
- Vol. 12 (1) , 73
Implementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round
Colorectal cancer (CRC) is the most common cancer in Europe with a mortality rate of almost 50%. The prognosis of patients is largely determined by the clinical and pathological stage at the time of diagnosis. Population screening has been shown to reduce CRC-related mortality rate. Most screening programs worldwide rely on fecal immunochemical testing (FIT). The effectiveness of a FIT screening program is not only influenced by initial participation rate, but also by program adherence during consecutive screening rounds. We aim to evaluate the participation rate in and yield of a third CRC screening round using FIT. Four years after the first screening round and two years after the second round, a total number of approximately 11,000 average risk individuals (50 to 75 years of age) will be invited to participate in a third round of FIT-based CRC screening. We will select individuals in the same target area as in the previous screening rounds, using the electronic database of the regional municipal administration registrations. We will invite all FIT-negatives and all non-participants in previous screening rounds, as well as eligible first time invitees who have moved into the area or have become 50 years of age. FITs will be analyzed in the special technique laboratory of the Academic Medical Center of the University of Amsterdam. All FIT-positives will be invited for a consultation at the outpatient clinic. In the absence of contra-indications, a colonoscopy will follow at the Academic Medical Center or at the Flevohospital. The primary outcome measures are the participation rate, defined as the proportion of invitees that return a FIT in this third round of FIT-screening, and the diagnostic yield of the program. This study will provide precise data on the participation in later FIT screening rounds. This enables to estimate the effectiveness of CRC screening programs that rely on repeated FIT- screening, such as the one that will be implemented in the Netherlands in 2013.
- 19 June 2012
- Published by Springer Nature in BMC Gastroenterology
- Vol. 12 (1) , 73
Open AccessImplementation of population screening for colorectal cancer by repeated Fecal Immunochemical Test (FIT): third round
Colorectal cancer (CRC) is the most common cancer in Europe with a mortality rate of almost 50%. The prognosis of patients is largely determined by the clinical and pathological stage at the time of diagnosis. Population screening has been shown to reduce CRC-related mortality rate. Most screening programs worldwide rely on fecal immunochemical testing (FIT). The effectiveness of a FIT screening program is not only influenced by initial participation rate, but also by program adherence during consecutive screening rounds. We aim to evaluate the participation rate in and yield of a third CRC screening round using FIT. Four years after the first screening round and two years after the second round, a total number of approximately 11,000 average risk individuals (50 to 75 years of age) will be invited to participate in a third round of FIT-based CRC screening. We will select individuals in the same target area as in the previous screening rounds, using the electronic database of the regional municipal administration registrations. We will invite all FIT-negatives and all non-participants in previous screening rounds, as well as eligible first time invitees who have moved into the area or have become 50 years of age. FITs will be analyzed in the special technique laboratory of the Academic Medical Center of the University of Amsterdam. All FIT-positives will be invited for a consultation at the outpatient clinic. In the absence of contra-indications, a colonoscopy will follow at the Academic Medical Center or at the Flevohospital. The primary outcome measures are the participation rate, defined as the proportion of invitees that return a FIT in this third round of FIT-screening, and the diagnostic yield of the program. This study will provide precise data on the participation in later FIT screening rounds. This enables to estimate the effectiveness of CRC screening programs that rely on repeated FIT- screening, such as the one that will be implemented in the Netherlands in 2013.
- 4 November 2011
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 43 (11) , 949
Systematic review of endoscopic mucosal resection versus transanal endoscopic microsurgery for large rectal adenomas
Barendse RM et al. Systematic review of endoscopic mucosal resection versus transanal endoscopic microsurgery for large rectal adenomas. Endoscopy 2011; 43: published online 04. 10. 2011 This article was published e-first as Review and appears as Original article in this current issue.
- 4 November 2011
- Published by Georg Thieme Verlag KG in Endoscopy
- Vol. 43 (11) , 949
Systematic review of endoscopic mucosal resection versus transanal endoscopic microsurgery for large rectal adenomas
Barendse RM et al. Systematic review of endoscopic mucosal resection versus transanal endoscopic microsurgery for large rectal adenomas. Endoscopy 2011; 43: published online 04. 10. 2011 This article was published e-first as Review and appears as Original article in this current issue.
- 1 June 2011
- Published by Georg Thieme Verlag KG in Endoskopie heute
- Vol. 24 (02) , 109-116
NBI versus hochauflösende Endoskopie in der Diagnostik von Neoplasien bei Colitis ulcerosa
Hintergrund und Studienziele: Welche koloskopische Technik für die Diagnostik von Neoplasien bei Patienten mit Colitis ulcerosa am sensitivsten ist, darüber bestehen unterschiedliche Ansichten. Wir verglichen das Narrow-Band-Imaging (NBI) einer neuen Generation mit hochauflösender (high-definition) Endoskopie (HDE) bei der Detektion von Neoplasien und evaluierten NBI bei der Unterscheidung zwischen neoplastischer und nicht-neoplastischer Mukosa. Patienten und Methoden: In einer randomisierten Crossvover-Studie wurden Colitis-ulcerosa-Patienten sowohl mit NBI als auch HDE-Koloskopie untersucht, wobei zumindest 3 Wochen zwischen den beiden Prozeduren lagen, die von unterschiedlichen Endoskopikern durchgeführt wurden. Die Läsionen, die bei der Erstuntersuchung detektiert wurden, verblieben in situ, um sie bei der 2. Untersuchung ebenfalls auffinden zu können. Zielkriterien waren 1. die Detektion von Neoplasien, 2. die diagnostische Genauigkeit von NBI bei der Unterscheidung zwischen neoplastischer und nicht-neoplastischer Mukosa anhand der KUDO-Klassifikation und der vaskulären Gefäßintensität (VPI). Ergebnisse: 25 Patienten wurden zuerst zur HDE randomisiert, 26 primär zu NBI. Von 16 neoplastischen Läsionen wurden 11 (69 %) durch HDE und 13 (81 %) durch NBI detektiert (p = 0,727). Von 11 Patienten mit Neoplasien wurden 9 (82 %) durch HDE und 8 (73 %) durch NBI detektiert (p = 1,0). Für die KUDO-Klassifikation betrugen Sensitivität 76 %, Spezifität 66 % und die Accuracy 67 %. Für die VPI betrugen die Sensitivität 80 %, die Sepzifität 72 % und die Accuracy 73 %. Schlussfolgerung: NBI verbessert im Vergleich zur HDE bei Patienten mit Colitis ulcerosa die Detektion der Neoplasien nicht. NBI lieferte bei der Unterscheidung zwischen neoplastischer und nicht-neoplastischer Mukosa unbefriedigende Resultate. Background and study aims: Controversy exists about which colonoscopic technique is most sensitive for the diagnosis of neoplasia in patients with ulcerative colitis. We compared new-generation narrow-band imaging (NBI) to high-definition endoscopy (HDE) for the detection of neoplasia and evaluated NBI for the differentiation of neoplastic from non-neoplastic mucosa. Patients and methods: Randomized crossover trial in which patients with ulcerative colitis underwent both NBI and HDE colonoscopy in random order with at least 3 weeks between the two procedures, which were performed by different endoscopists. Lesions detected during the first examination were left in situ in order to enable detection during the second examination as well. Main outcome measures were (1) neoplasia detection, and (2) diagnostic accuracy of NBI for differentiating neoplastic from non-neoplastic mucosa by using the Kudo classification and vascular pattern intensity (VPI). Results: Twenty-five patients were randomized to undergo HDE first and 23 to undergo NBI first. Of 16 neoplastic lesions, 11 (69 %) were detected by HDE and 13 (81 %) by NBI (P = 0.727). Of 11 patients with neoplasia, 9 (82 %) were diagnosed by HDE and 8 (73 %) by NBI (P = 1.0). The sensitivity, specificity, and accuracy of the Kudo classification were 76 %, 66 % and 67 %. Corresponding figures for VPI were 80 %, 72 % and 73 %. Conclusion: NBI does not improve the detection of neoplasia in patients with ulcerative colitis compared to HDE. In addition, NBI proves unsatisfactory for differentiating neoplastic from non-neoplastic mucosa.
- 1 June 2011
- Published by Georg Thieme Verlag KG in Endoskopie heute
- Vol. 24 (02) , 109-116
NBI versus hochauflösende Endoskopie in der Diagnostik von Neoplasien bei Colitis ulcerosa
Hintergrund und Studienziele: Welche koloskopische Technik für die Diagnostik von Neoplasien bei Patienten mit Colitis ulcerosa am sensitivsten ist, darüber bestehen unterschiedliche Ansichten. Wir verglichen das Narrow-Band-Imaging (NBI) einer neuen Generation mit hochauflösender (high-definition) Endoskopie (HDE) bei der Detektion von Neoplasien und evaluierten NBI bei der Unterscheidung zwischen neoplastischer und nicht-neoplastischer Mukosa. Patienten und Methoden: In einer randomisierten Crossvover-Studie wurden Colitis-ulcerosa-Patienten sowohl mit NBI als auch HDE-Koloskopie untersucht, wobei zumindest 3 Wochen zwischen den beiden Prozeduren lagen, die von unterschiedlichen Endoskopikern durchgeführt wurden. Die Läsionen, die bei der Erstuntersuchung detektiert wurden, verblieben in situ, um sie bei der 2. Untersuchung ebenfalls auffinden zu können. Zielkriterien waren 1. die Detektion von Neoplasien, 2. die diagnostische Genauigkeit von NBI bei der Unterscheidung zwischen neoplastischer und nicht-neoplastischer Mukosa anhand der KUDO-Klassifikation und der vaskulären Gefäßintensität (VPI). Ergebnisse: 25 Patienten wurden zuerst zur HDE randomisiert, 26 primär zu NBI. Von 16 neoplastischen Läsionen wurden 11 (69 %) durch HDE und 13 (81 %) durch NBI detektiert (p = 0,727). Von 11 Patienten mit Neoplasien wurden 9 (82 %) durch HDE und 8 (73 %) durch NBI detektiert (p = 1,0). Für die KUDO-Klassifikation betrugen Sensitivität 76 %, Spezifität 66 % und die Accuracy 67 %. Für die VPI betrugen die Sensitivität 80 %, die Sepzifität 72 % und die Accuracy 73 %. Schlussfolgerung: NBI verbessert im Vergleich zur HDE bei Patienten mit Colitis ulcerosa die Detektion der Neoplasien nicht. NBI lieferte bei der Unterscheidung zwischen neoplastischer und nicht-neoplastischer Mukosa unbefriedigende Resultate. Background and study aims: Controversy exists about which colonoscopic technique is most sensitive for the diagnosis of neoplasia in patients with ulcerative colitis. We compared new-generation narrow-band imaging (NBI) to high-definition endoscopy (HDE) for the detection of neoplasia and evaluated NBI for the differentiation of neoplastic from non-neoplastic mucosa. Patients and methods: Randomized crossover trial in which patients with ulcerative colitis underwent both NBI and HDE colonoscopy in random order with at least 3 weeks between the two procedures, which were performed by different endoscopists. Lesions detected during the first examination were left in situ in order to enable detection during the second examination as well. Main outcome measures were (1) neoplasia detection, and (2) diagnostic accuracy of NBI for differentiating neoplastic from non-neoplastic mucosa by using the Kudo classification and vascular pattern intensity (VPI). Results: Twenty-five patients were randomized to undergo HDE first and 23 to undergo NBI first. Of 16 neoplastic lesions, 11 (69 %) were detected by HDE and 13 (81 %) by NBI (P = 0.727). Of 11 patients with neoplasia, 9 (82 %) were diagnosed by HDE and 8 (73 %) by NBI (P = 1.0). The sensitivity, specificity, and accuracy of the Kudo classification were 76 %, 66 % and 67 %. Corresponding figures for VPI were 80 %, 72 % and 73 %. Conclusion: NBI does not improve the detection of neoplasia in patients with ulcerative colitis compared to HDE. In addition, NBI proves unsatisfactory for differentiating neoplastic from non-neoplastic mucosa.